PAMIDRONATE HOSPIRA 3mg / ml perfusive solution concentrate medication leaflet

M05BA03 pamidronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates

Pamidronic acid is a bisphosphonate used to treat hypercalcemia associated with cancer and to prevent skeletal complications in patients with bone metastases. It works by inhibiting osteoclast-mediated bone resorption, thereby reducing bone loss.

It is administered intravenously and is effective in lowering high calcium levels in the blood, which can occur in certain types of cancer. It is also used to reduce the risk of bone fractures and other complications in patients with bone metastases.

Common side effects include fever, flu-like symptoms, and bone or muscle pain. In rare cases, it may cause osteonecrosis of the jaw, especially in patients who have recently undergone dental procedures.

Patients receiving pamidronic acid treatment should be monitored for kidney function, as the drug can affect the kidneys, particularly at high doses.

General data about PAMIDRONATE HOSPIRA 3mg / ml

Substance: pamidronic acid

Date of last drug list: 01-06-2025

Commercial code: W68901001

Concentration: 3mg / ml

Pharmaceutical form: perfusive solution concentrate

Quantity: 1

Product type: original

Price: 242.66 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PFIZER HOLDING FRANCE - FRANTA

Holder: PFIZER ROMANIA S.R.L. - ROMANIA

Number: 717/2022/01

Shelf life: 3 years

Concentrations available for pamidronic acid

15mg, 15mg/ml, 30mg, 3mg/ml, 60mg, 6mg/ml, 9mg/ml

Compensation lists for PAMIDRONATE HOSPIRA 3mg / ml PFIZER

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

242.66 RON

242.66 RON

0.00 RON

NHP 6.6 (C2) - Imperfect osteogenesis

Price

Copayment

Patient

242.66 RON

242.66 RON

0.00 RON